Pre-emptive pharmacogenomics (PPGx) involves testing an individual’s genes beforehand to identify genetic variations that raise the risk of negative reactions to specific medications. This proactive testing can expedite drug selection in emergencies by identifying suitable medications based on a patient’s genetic profile.
A pilot study funded by Precision Health Research Singapore (PRECISE) and led by the NUS Medical Organization, including the NUS Saw Swee Hock School of Public Health, aims to incorporate pre-emptive pharmacogenomics (PPGx) into routine clinical practise.
Learn how PPGx helps doctors personalise treatment and improve patient outcomes.